Transcriptomics and metabolomics analyses indicate that SRL primarily modulates the adenosine monophosphate-activated protein kinase (AMPK) and peroxisome proliferator-activated receptors (PPAR) signaling pathways by regulating genes such as Scd, Fads2, Cpt1a, Lipe, Pfkfb3, and Hmgcs2. Thereby influencing biomarkers such as S-Adenosylmethioninamine (SAM), 16-hydroxyhexadecanoic acid, and proline, mitigating metabolic disorders in pathways such as arginine and proline metabolism, vitamin B6 metabolism, fatty acid degradation, and arachidonic acid metabolism. The gene discussed is PPARA; the disease is metabolic disease.